NCT03383042 - Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

November 23, 2018

Study Completion Date

April 5, 2019

Conditions

Anti-Ulcer Agents

Interventions

DRUG

Cohort 1 (JP-1366 A mg)

Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 2 (JP-1366 B mg)

Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 3 (JP-1366 C mg)

Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 4 (JP-1366 D mg)

Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 5 (JP-1366 E mg)

Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 6 (JP-1366 F mg)

Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 7 (JP-1366 G mg)

Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 8 (JP-1366 H mg)

Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg

DRUG

Cohort 9 (JP-1366 I mg)

Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg

Trial Locations (1)

Seoul National University Hospital(SNUH), Seoul